Table 2. Included Studies.

BRT: brachytherapy; Cs-131: Cesium-131; Gd - grade using the Common Terminology Criteria for Adverse Events (CTCAE, version 5.0); HGG: high-grade glioma; I-125: Iodine-125; Ir-192: Iridium-192; LRT-BRT: time from first last radiation therapy to brachytherapy; Mening: meningioma; Mets: metastases; NR: not reported; OS: overall survival; PCC: prospective case-control; PCS: prospective case series; RCC: retrospective case-control; RCS: retrospective case series; RN: radiation necrosis; RT: radiation therapy; TB: tumor border; Tx: treatment

	Study	N	Study   Type	Tumor  Type	Type of   Implant	Source	Median   Dose (Gy)	Depth (mm)	LRT-BRT (mo.)	RN % (Gd 3)	RN % (Gd 4)	OS BRT   (mo)	Study  Quality
1	Chan et al. [16]	24	PCS	HGG	Intracavitary	I-125 GliaSite	53*	5	NR	8.3	8.3	9.1	4
2	Gabayan et al. [17]	95	RCS	HGG	Intracavitary	I-125 GliaSite	60	10	12.6	2.1	2.1	9.1	4
3	Tselis et al. [29]	84	RCS	HGG	Interstitial	Ir-192	40	TB	NR	2.4	0	9.2	4
4	Darakchiev et al. [5]	34	PCS	HGG	Intracavitary	I-125	120	5	NR	23.5	11.8	17.2	4
5	Fabrini et al. [28]	21	RCS	HGG	Intracavitary	Ir-192	18	5	8.6	0	0	5.5	4
6	Gobitti et al. [18]	15	RCS	HGG	Intracavitary	I-125 GliaSite	45	10	28	20	20	13	4
7	Archavlis et al. [26]	46	PCC	HGG	Interstitial	Ir-192	40	TB	NR	8.7	0	8	3
8	Schwartz et al. [25]	68	RCS	HGG	Interstitial	1-125	50	TB	NR	8.8	0	13.4	4
9	Chatzikonstantinou et al. [27]	135	RCS	HGG	Interstitial	Ir-192	40	TB	9.3	2.2	2.2	9.2	4
10	Magill et al. [21]	42	RCS	Mening	Intracavitary	I-125	120	5	NR	19	11.9	39.6	4
11	Brachman et al. [3]	19	PCS	Mening	Intracavitary	Cs-131	63	5	NR	10.5	0	26	4
12	Koch et al. [20]	15	RCS	Mening	Intracavitary	I-125 / Cs-131	100	5	14	40	0	12.5	4
13	Mooney et al. [22]	11	RCC	Mening	Intracavitary	I-125 / Cs-131	100	5	NR	27.3	0	NR	3
14	Huang et al. [19]	21	RCS	Mets	Intracavitary	I-125	300	5	11.1	19	10	7.3	4
15	Ruge et al. [24]	27	RCS	Mets	Interstitial	I-125	50	TB	9	0	0	14.8	4
16	Raleigh et al. [23]	38	RCS	Mets	Intracavitary	I-125	263	5	NR	25	0	12	4